Rivernorth Capital Management’s Orchestra BioMed OBIO Stock Holding History

Rivernorth Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,000	Closed	-$100K	–	885
2022 Q2	$100K	Hold	10,000	–	–	﹤0.01%	538
2022 Q1	$99K	Hold	10,000	–	–	﹤0.01%	561
2021 Q4	$101K	Hold	10,000	–	–	﹤0.01%	493
2021 Q3	$99K	Hold	10,000	–	–	0.01%	406
2021 Q2	$102K	Hold	10,000	–	–	0.01%	396
2021 Q1	$112K	Hold	10,000	–	–	0.01%	349
2020 Q4	$128K	Hold	10,000	–	–	0.01%	291
2020 Q3	$110K	Buy	+10,000	New	+$112K	0.01%	272

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Rivernorth Capital Management's OBIO Position: Q3 2022 in Review

Rivernorth Capital Management sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 10,000 shares — an estimated $100K sold.

Rivernorth Capital Management first reported a position in OBIO in Q3 2020 and held it in 8 quarters. The position peaked at $128K in Q4 2020. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

Rivernorth Capital Management reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
Rivernorth Capital Management sold 10,000 Orchestra BioMed shares in Q3 2022, an estimated $100K.
Rivernorth Capital Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 8 quarters.
Rivernorth Capital Management's Orchestra BioMed position peaked at $128K in Q4 2020.
23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Rivernorth Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.